Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of cefpodoxime proxetil capsules in China. Welcome to wholesale bulk high quality cefpodoxime proxetil capsules for sale here from our factory. Good service and reasonable price are available.
Cefpodoxime proxetil capsules are a third-generation oral broad-spectrum cephalosporin antibiotic. As a prodrug, they have no antibacterial activity and need to be hydrolyzed by esterases in the gastrointestinal tract to produce the active metabolite Cefpodoxime. The latter inhibits the cross-linking of peptidoglycan chains by specifically binding to penicillin binding proteins (PBPs) in bacterial cell walls, leading to cell wall defects and bacterial rupture and death due to osmotic pressure imbalance. This mechanism enables it to have strong bactericidal effects on most Gram positive bacteria (such as Streptococcus pneumoniae, Streptococcus genus) and Gram negative bacteria (such as Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli), while maintaining activity against some strains that produce β - lactase.
Pharmacokinetic advantages:
Oral bioavailability is about 50%, and food can significantly improve absorption efficiency (Cmax increases by 15% -24%, AUC increases by 21% -33%). The drug is widely distributed in the respiratory tract, urinary tract, and skin soft tissues, with a low protein binding rate (21% -29%) and a high proportion of free drugs to ensure target tissue concentration. Metabolism mainly relies on gastrointestinal esterases, without the involvement of liver cytochrome P450 enzymes, reducing the risk of liver toxicity. About 60% is excreted in its original form through the kidneys, with a half-life of 2-3 hours, supporting a twice daily dosing regimen.
Additional information of chemical compound:
| Product Name | Cefpodoxime Proxetil Powder | Cefpodoxime Proxetil Tablets | Cefpodoxime Proxetil Liquid | Cefpodoxime Proxetil Capsules |
| Product Type | Powder | Tablets | Liquid | Capsules |
| Product Purity | ≥99% | ≥99% | ≥99% | ≥99% |
| Product Specifications | Customizable | Customizable | Customizable | Customizable |
| Product Package | Customizable | Customizable | Customizable | Customizable |
Our product form
Cefpodoxime Proxetil +. COA
 |
||
Certificate of Analysis |
||
| Compound name | Cefpodoxime Proxetil | |
| CAS No. | 87239-81-4 | |
| Grade | Pharmaceutical grade | |
| Quantity | Customized | |
| Packaging standard | Customized | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 20250109001 | |
| MFG | Jan 12th 2025 | |
| EXP | Jan 8th 2029 | |
| Structure |
|
|
| TEST STANDARD | GB/T24768-2009 Industry. Stnndard | |
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤4.5% | 0.30% |
| Loss on drying | ≤1.0% | 0.15% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.5% |
| Single impurity | <0.8% | 0.48% |
| Residue on ignition | <0.20% | 0.064% |
| Total microbial count | ≤750cfu/g | 80 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 400ppm |
| Storage | Store in a sealed, dark and dry place at-20 degrees | |
|
|
||
Mastitis is more common in lactating women and is mainly caused by bacteria such as Staphylococcus aureus. Patients may experience redness, swelling, and pain in their breasts, with locally elevated temperatures and sometimes accompanied by systemic symptoms such as fever. Cefpodoxime proxetil capsules can inhibit bacterial cell wall synthesis, kill bacteria that cause mastitis, alleviate breast inflammation, relieve symptoms, and promote milk secretion. When treating mastitis, patients should be encouraged to breastfeed more or use a breast pump to extract milk to maintain breast patency.
Vestibular gland inflammation and vestibular gland abscess
The vestibular gland is located in the posterior part of the female labia majora. When bacterial infection causes vestibular gland inflammation, a red, swollen, and painful lump appears in the lower one-third of the labia majora, and in severe cases, an abscess may form. Cefotaxime ester dry suspension has antibacterial effects on common bacteria that cause vestibular gland inflammation, can control infection, promote inflammation resolution or abscess absorption. For patients who have already developed abscesses, incision and drainage surgery is required, and the medication should be used for anti infective treatment after surgery.
Periodontitis is a chronic inflammation of periodontal tissue, while periapical periodontitis is an inflammation of the soft tissue surrounding the dental crown that occurs when wisdom teeth do not fully erupt or are obstructed. Cefotaxime ester dry suspension can assist in the treatment of periodontitis and periapical periodontitis caused by sensitive bacteria, reduce symptoms such as gum redness, pain, and bleeding, and promote inflammation resolution. When treating periodontitis and crown periodontitis, oral hygiene guidance should be provided simultaneously, such as brushing teeth correctly and using dental floss.
Cefpodoxime proxetil are a third-generation oral cephalosporin antibiotic, and its mechanism of action involves multiple biological and pharmacological aspects.
Fundamentals of Chemical Structure
The chemical name of cefpodoxime axetil is (±) -1-hydroxyethyl (+) - (6R, 7R) -7- [2- (2-amino-4-thiazolyl) glyoxylate] -3- (methoxymethyl) -8-oxo-5-thio-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate, 72- (Z) - (O-methyloxime) isopropyl carbonate, with a molecular formula of C21H27N5O9S2 and a molecular weight of 557.6. Its structural features include:
Cefotaxime skeleton: There is a methoxythiazole group at position 7, a methoxymethyl group at position 3, and a proxetil group (isopropoxycarbonyloxyethyl) on the carboxylic acid at position 4.
Precursor drug design: The presence of proxetil groups makes it an inactive prodrug that needs to be hydrolyzed in vivo to release the active ingredient Cefpodoxime.
This structure not only ensures the oral absorption efficiency of the drug, but also prolongs the half-life of the drug in the body through prodrug design, enhancing the antibacterial effect.
Precursor drug characteristics and in vivo conversion
Cefpodoxime axetil capsules themselves have no antibacterial activity, and their action depends on the conversion process in the body after oral administration:
Absorption and hydrolysis: After oral administration, cefpodoxime axetil is hydrolyzed by non-specific esterases in the gastrointestinal tract, releasing the active metabolite cefpodoxime. This process mainly occurs in the intestinal wall and liver, ensuring that the drug is converted before entering the bloodstream.
Antibacterial target: Penicillin binding proteins (PBPs)
Cefotaxime exerts antibacterial effects by inhibiting bacterial cell wall synthesis, with its core target being penicillin binding proteins (PBPs):
The function of PBPs: PBPs are key enzymes in the synthesis of peptidoglycans in bacterial cell walls, including transpeptidases, carboxypeptidases, and endopeptidases, responsible for catalyzing the cross-linking of peptidoglycan chains, maintaining the integrity and mechanical strength of the cell wall.
The mechanism of action of cefuroxime:
Binding specificity: Cefotaxime binds with high affinity to PBPs (especially PBP1A, PBP1B, PBP2, and PBP3), inhibiting their enzymatic activity.
Blocked cell wall synthesis: The inactivation of PBPs leads to the inability of peptidoglycan chains to crosslink, resulting in cell wall defects. The bacterial cells swell and deform due to osmotic pressure imbalance, ultimately leading to rupture and death.
Time dependence of bactericidal concentration: Cefotaxime has a bactericidal concentration of 1-4 times the minimum inhibitory concentration (MIC) against Enterobacteriaceae bacteria (including β - lactase producing strains); The bactericidal rate against Haemophilus influenzae and Moraxella catarrhalis (including β - lactase producing strains) can reach 99.9% within 6 hours (concentration ≤ 4 times MIC).
Antibacterial spectrum and antibacterial activity
Cefpodoxime proxetil capsules have potent antibacterial activity against various Gram positive and Gram negative bacteria:
Gram positive bacteria:
Streptococcus genus: including Group A β - hemolytic streptococcus (GAS), Streptococcus pneumoniae (also effective against penicillin insensitive strains), Streptococcus agalactiae, etc.
Staphylococcus genus: Effective against methicillin-resistant Staphylococcus aureus and coagulase negative Staphylococcus aureus, but ineffective against methicillin-resistant Staphylococcus aureus (MRSA).
Gram negative bacteria:
Haemophilus influenzae: including strains that produce β - lactase.
Catamora: a pathogen that often causes respiratory infections.
Enterobacteriaceae: such as Escherichia coli, Klebsiella, Proteobacter, etc. (ineffective against strains producing extended spectrum beta lactases (ESBLs)).
Neisseria gonorrhoeae: A single dose of 200mg can effectively treat simple gonorrhea.
Other pathogenic bacteria: also have certain activity against Neisseria gonorrhoeae, Citrobacter, Salmonella, Shigella, etc.
Bacterial resistance mechanism
Although cefuroxime axetil capsules maintain high sensitivity to most pathogens, the issue of drug resistance still needs attention:
β - lactase production: Some Gram negative bacteria (such as Escherichia coli and Klebsiella) can inactivate cefuroxime by producing β - lactase to hydrolyze its β - lactam ring. However, cefoperazone is still effective against some strains that produce β - lactase, thanks to the stability of its methoxythiazole group on the enzyme.
PBPs variation: Bacteria can reduce the binding affinity of cefuroxime by altering the structure of PBPs, leading to drug resistance. For example, the resistance of Streptococcus pneumoniae to macrolide lincosamide streptomycin (MLS) antibiotics may be associated with variations in PBPs.
Overexpression of efflux pumps: Some bacteria use efflux pumps to expel cefoperazone from the extracellular space, reducing intracellular drug concentration and leading to drug resistance.
Clinical resistance rate: Domestic studies have shown that cefuroxime axetil is effective against Streptococcus pneumoniae GAS, The resistance rate of Haemophilus influenzae (including β - lactase producing strains) is low, but it is ineffective against methicillin-resistant Staphylococcus aureus, ESBLs producing Escherichia coli, and other bacteria.
Cefpodoxime Proxetil Capsules, as the third-generation oral cephalosporin antibiotics, have pharmacokinetic properties that directly affect clinical efficacy and safety.
Cefpodoxime is an inactive prodrug that needs to be hydrolyzed by non-specific gastrointestinal esterases to produce the active metabolite Cefpodoxime after oral administration in order to exert antibacterial effects.
Bioaccumulation: Under fasting conditions, the absolute bioavailability is about 50%, and food can significantly improve its absorption efficiency. Studies have shown that co administration with food can increase the peak blood concentration (Cmax) by 15% -24% and the area under the drug time curve (AUC) by 21% -33%. This characteristic originates from the promoting effect of food on the dissolution of pills, reducing the retention time of drugs in the gastrointestinal tract and thus reducing the first pass effect.
Dose dependence: Pharmacokinetic parameters exhibit a dose-dependent relationship. After oral administration of 0.1g, 0.2g, and 0.4g, the Cmax reached 1.4mg/L, 2.3mg/L, and 3.9mg/L, respectively, with a peak time (Tmax) of 2-3 hours. When a single dose of 400mg is administered, the blood drug concentration remains at 0.38mg/L for 6 hours, which is 1-4 times the MIC of most pathogens, ensuring the bactericidal effect.
Cefotaxime is widely distributed in the body and can penetrate to infected areas such as the respiratory tract, urinary tract, skin, and soft tissues
Organizational concentration: The concentration in lung tissue, tonsils, and skin blister fluid is 2.7 times, 0.17 times, and 0.4-0.7 times that of plasma, respectively. For example, after oral administration of 0.2g, the lung tissue concentration reached 0.63mg/L and the tonsil tissue concentration was 0.24mg/L, significantly higher than the MIC values of most pathogens.
Protein binding rate: The binding rate to plasma proteins is low (21% -29%), and the proportion of free drugs is high, which is beneficial for penetrating cell membranes and tissue barriers, and exerting antibacterial effects.
The metabolism of cefuroxime axetil mainly relies on gastrointestinal esterase hydrolysis, without the involvement of liver cytochrome P450 enzymes. Therefore:
Single metabolic pathway: About 90% of the dose is converted to cefpodoxime in the gastrointestinal tract, with only a small amount (<10%) entering the liver in its original form or metabolite form, significantly reducing the risk of liver toxicity.
No drug interaction: When used in combination with antacids or H2 receptor antagonists, the latter can lower the pH value in the stomach, inhibit esterase activity, and lead to a decrease in absorption of cefuroxime axetil, resulting in a 30% -50% decrease in Cmax. Therefore, it is recommended to avoid taking this type of medication together.
Cefotaxime is mainly excreted through the kidneys, with a half-life (t1/2) of 1.9-3.7 hours:
Excretion pathway: About 60% of the dose is excreted in its original form through glomerular filtration and tubular secretion, 29% -33% is excreted in the form of cefuroxime, and a small amount is excreted through bile.
Half life advantage: Although the half-life is short, its bactericidal concentration can be maintained for 6-8 hours, supporting a twice daily dosing regimen. For example, after oral administration of 0.2g, the blood drug concentration remained at 0.18mg/L for 12 hours, maintaining inhibitory effects on most pathogens.
Frequently Asked Questions
What is the drug cefpodoxime proxetil used for?
+
-
Cefpodoxime is used to treat bacterial infections in many different parts of the body.It belongs to the class of medicines known as cephalosporin antibiotics.It works by killing bacteria or preventing their growth.However, this medicine will not work for colds, flu, or other virus infections.
Can I take cefpodoxime for 3 days?
+
-
Please do not restart cefpodoxime without consulting your doctor first.Stopping an antibiotic early (after only three days) often allows the bacteria to return and potentially become resistant.
Is cefpodoxime bad for the kidneys?
+
-
Kidney damage can happen when taking cefpodoxime.Call your healthcare provider right away if you have any of the following symptoms of kidney damage.Severe Skin Reactions.
Is cefpodoxime before or after food?
+
-
Take the suspension with food;the tablet may be taken with or without food .Take cefuroxime at around the same times every day.Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand.
Is cefpodoxime bad for your liver?
+
-
Hot Tags: cefpodoxime proxetil capsules, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale